Deletion of 9p21.3 is more enriched in tumors with high immune infiltrations and is associated with worse prognostic outcomes in ccRCC after anti-PD-1 therapy (26), indicating that ICB therapeutic efficacy in the C2 cluster might be higher than in the C1 cluster. Here, PDCD1 is linked to nonpapillary renal cell carcinoma.